Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G2-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells

Cancer Research

Volumn 62, Issue 20, 2002, Pages 5711-5719

  Moon, Eun Yi ^a   Lerner, Adam ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLAMINE DERIVATIVE; CALCIUM CHELATING AGENT; CP 248; CP 461; CYCLIC GMP; CYCLIC GMP PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE; DOXORUBICIN; ETOPOSIDE; PHOSPHODIESTERASE INHIBITOR; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL SHAPE; CHRONIC LYMPHATIC LEUKEMIA; COLON CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; GENOTOXICITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MICROTUBULE; MITOSIS INHIBITION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SIZE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; G2 PHASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MICROTUBULES; MITOSIS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; SULINDAC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0037108708     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Vane, J. R., Bakhle, Y. S., and Botting, R. M. Cyclooxygenases 1 and 2. Ann. Rev. Pharmacol. Toxicol., 38: 97-120, 1998.
2. Waddell. W. R., and Loughry, R. W. Sulindac for polyposis of the colon. J. Surg. Oncol., 24: 83-87, 1983.
3. Steinbach, G., Lynch,. P. M., and Phillips, R. K. S. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342: 1946-1952, 2000.
4. Piazza. G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T., Bogert, C., Guillen, J. M., Brendel, K, Gross, P. H., Sped, G., Ritchie, J., Burt, R. W., Ellsworth, L., Ahnen, D. J., and Pamukcu, R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57: 2909-2915, 1997.
5. Thompson, H. J., Jiang, C., Lu, J., Mehta, R. G., Piazza, G. A., Paranka, N. S., Pamukcu, R., and Ahnen, D. J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res., 57: 267-271, 1997.
6. Piazza, G. A., Rahm, A. K., Finn, T. S., Fryer, B. H., Li, H., Stoumen, A. L., Pamukcu, R., and Ahnen, D. J. Apoptosis primarily accounts for the growth inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res., 57: 2452-2459, 1997.
7. Van Stolk, R. U., Stoner, G., Hayton, W., Chan, K., DeYoung, B., Kresty, L., Kemmenoe, B. H., Elson, P., Rybicki, L., Church, J. M., Provencher, K., McLain, D., Hawk, E., Fryer, B., Kelloff. G., Ganapathi, R., and Budd, G. T. A Phase 1 trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventative agent in patients with familial adenomatous polyposis. Clin. Cancer Res., 6: 78-89, 2000.
8. Tong-Chuan, H., Chan, T. A., Vogelstein, B., and Kinzler, J. W. PPARδ is an APC-regulated target of non-steroidal anti-inflammatory drugs. Cell, 99: 335-345, 1999.
9. Yamamoto, Y., Yin, M-J., Lin, K-M., and Gaynor, R. B. Sulindac inhibits activation of the NF-κB pathway. J. Biol. Chem., 274: 27307-27314, 1999.
10. Thompson, W. J., Piazza, G. A., Li, H., Liu, L., Fewtter, J., Zhu, B., Sperl, G., Ahnen, D., and Pamukcu, R. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res., 60: 3338-3342, 2000.
11. 2-terminal kinase 1. Clin. Cancer Res., 6: 4136-4141, 2000.
12. Kim, D. H., and Lerner, A. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood, 92: 2484-2494, 1998.
13. Lerner, A., Kim, B., and Lee, R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk. Lymphoma, 37: 39-51, 2000.
14. Mohammad, R., Mohamed. A., Hamdan, M., Vo, T., Chen, B., Katato, K., Abubakr, Y., Dugan, M., and al-Katib. A. Establishment of a human B-CLL xenograft model: Utility as a preclinical model. Leukemia (Baltimore), 10: 130-137, 1996.
15. Rai, K. A critical analysis of staging in CLL. In: R. Gale and K. Rai (eds.), Chronic Lymphocytic Leukemia: Recent Progress and Future Directions, Vol. 59, p. 253. New York: Alan R. Liss, 1987.
16. Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D., and Boyd, M. R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res., 48: 4827-4833, 1988.
17. Anand, B., and Chou, I. Microtubules and microtubule-associated proteins in resting and mitogenically activated normal human peripheral blood T cells. J. Biol. Chem., 267: 10716-10722, 1992.
18. Whitney, R. B., and Sutherland, R. M. Characteristics of Ca+ accumulation by lymphocytes and alterations in the processing induced by phytohemagglutinin. J. Cell Physiol., 82: 9-20, 1973.
19. Evans, T., Rosenthal, E. T., Youngblom, J., Distel, D., and Hunt, T. Cyclin: A protein specified by maternal RNA in sea urchin eggs that is destroyed at each cleavage division. Cell, 33: 389-396, 1983.
20. Buchkovich, K., Duffy, L. A., and Harlow, E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell, 58: 1097-1105, 1989.
21. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825. 1993.
22. 2/M transition by p53. Oncogene, 20: 1803-1815, 2001.
23. Zhen, W., Denault, C. M., Loviscek, K., Walter, S., Geng, L., and Vaughan, A. T. M. The relative radiosensitivity of TK6 and WI-L2-NS lymphoblastoid cells derived from a common source is primarily determined by their p53 status. Mutat. Res., 346: 85-92, 1995.
24. 2/M. Mol. Cell. Biol., 19: 8469-8478, 1999.
25. Srivastava, R. K., Srivastava, R. K., Korsmeyer, S. J., Nesterova, M., Cho-Chung, Y. S., and Longo, D. L. Involvement of microtubules in the regulation of bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell. Biol., 18: 3509-3517, 1998.
26. Blagosklonny, M. V., Giannakakou, P., El-Deity, W. S., Kingston, D. G. I., Higgs, P. I., Neckers, L., and Fojo. T. Rafl/Bcl2 phosphorylation: A step from microtubule damage to cell death. Cancer Res., 57: 130-135, 1997.
27. 2/M phases and its role in cell cycle regulation. J. Biol. Chem., 275: 21661-21667, 2000.
28. Vilpo, J. A., Koski, T., and Vilpo, L. M. Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur. J. Haematol., 65: 370-378, 2000.
29. Srivastava, R. K., Mi, Q. S., Hardwick, J. M., and Longo, D. L. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc. Natl. Acad. Sci. USA, 96: 3775-3780, 1999.
30. Wang, S., Wang, Z., Boise, L., Dent, P., and Grant, S. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochem. Biophys. Res. Comm., 259: 67-72, 1999.
31. Ling, Y-H., Tornos, C., and Perez-Soler, R. Phosphorylation of Bcl2 is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem., 273: 18984-18991, 1998.
32. 2 arrest after DNA damage. Science (Wash. DC), 282: 1497-1501, 1998.
33. Tishler, R. B., Lamppu, D. M., Park, S., and Price, B. D. Microtubule active drugs Taxol, vinblastine and nocodazole increase the levels of transcriptionally active p53. Cancer Res., 55: 6021-6025, 1995.
34. Stewart, Z. A., Tang, L. J., and Pietenpol, J. A. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene, 20: 113-124, 2001.
35. Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L., Raskind, W. H., and Reid, B. J. A p53-dependent mouse spindle checkpoint. Science (Wash. DC). 267: 1353-1356, 1995.
36. Di Leonardo, A., Khan, S. H., Linke, S. P., Greco, V., Seidita, G., and Wahl, G. M. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res., 57: 1013-1019, 1997.
37. Epstein, P. M., Moraski, S., and Hachisu, R. Identification and characterization of Ca2+-calmodulin-sensitive cyclic nucleotide phosphodiesterase in a human lymphoblastoid cell line. Biochem. J., 243: 533-539, 1987.
38. Tenor. H., Staniciu, L., Schudt, C., Hatzelmann, A., Wendel, A., Djukanovic, R., Church, M. K., and Shute, J. K. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes. Clin. Exp. Allergy., 25: 616-624. 1995.
39. Michie, A., Rena, G., Harnett, M., and Houslay, M. Upregulation of cAMP-specific PDE-4 activity following ligation of the TCR complex on thymocytes is blocked by selective inhibitors of protein kinase C and tyrosyl kinases. Cell Biochem. Biophys., 28: 161-185, 1998.
40. Fisher, D. A., Smith, J. F., Pillar, J. S., St. Denis, S. H., and Cheng, J. B. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem., 273: 15559-15564, 1998.
41. Jiang, X., Paskind, M., Weltzien, R., and Epstein, P. M. Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes. Cell Biochem. Biophys., 28: 135-160, 1998.
42. Fischer, T. A., Palmetshofer, A., Gambaryan, S., Butt, E., Jassoy, C., Walter, U., Sopper, S., and Lohmann, S. M. Activation of cGMP-dependent protein kinase Iβ inhibits interleukin 2 release and proliferation of T cell receptor-stimulated human peripheral T cells. J. Biol. Chem., 276: 5967-5974, 2001.
43. Zang, M., Waelde, C. A., Xiang, X., Rana, A., Wen, R., and Luo, Z. Microtubule integrity regulates Pak leading to Ras-independent activation of Raf-1. J. Biol. Chem., 276: 25157-25165, 2001.